

University of Groningen

## Lipids, inflammation, and the Renin-Angiotensin System

Harst, Pim van der

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2006

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Harst, P. V. D. (2006). *Lipids, inflammation, and the Renin-Angiotensin System*. s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# B

**BIBLIOGRAPHY**



## Bibliography

1. **Van der Harst P**, Voors AA, Volbeda M, Buikema H, Van Veldhuisen DJ, Van Gilst WH. Usefulness of Preoperative C-reactive Protein and Soluble Intercellular Adhesion Molecule 1 Level for Predicting Cardiovascular Events After Coronary Artery Bypass Grafting. *Am J Cardiol.* 2006; 97:1697-701.
2. **Van der Harst P**, Smilde TD, Buikema H, Voors AA, Navis G, van Veldhuisen DJ, van Gilst WH. Vascular function and mild renal impairment in stable coronary artery disease. *Arterioscler Thromb Vasc Biol.* 2006 Feb;26(2):379-84.
3. **Van der Harst P**, Wagenaar LJ, Buikema H, Voors AA, Plokker HW, Morshuis WJ, Six AJ, Boonstra PW, Nickenig G, Wassmann S, van Veldhuisen DJ, van Gilst WH. Effect of intensive versus moderate lipid lowering on endothelial function and vascular responsiveness to angiotensin II in stable coronary artery disease. *Am J Cardiol.* 2005 Nov 15;96(10):1361-4.
4. **Van der Harst P**, Voors AA, van Gilst WH, van Veldhuisen DJ. Statins and autonomic function in chronic heart failure. *Cardiovasc Drugs Ther.* 2005 May;19(3):167-8.
5. **Van der Harst P**, Kastelein JJ, van Gilst WH. [Statins: for the time being, do not as a rule prescribe the maximum dose] *Ned Tijdschr Geneesk.* 2005;149(46):2589. (Letter)
6. Asselbergs FW, **Van der Harst P**, Jessurun GA, Tio RA, van Gilst WH. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. *Vascul Pharmacol.* 2005 Feb;42(3):125-40.
7. **Van der Harst P**, Voors AA, van Veldhuisen DJ. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med.* 2004;351:714. (Letter)
8. **Van der Harst P**, Wiesfeld AC, van Gelder IC, van Tintelen JP, Suurmeijer AJ, van Veldhuisen DJ. [Arrhythmogenic right-ventricular cardiomyopathy: different manifestations as precursors of sudden death which might be prevented] *Ned Tijdschr Geneesk.* 2004;148:2396-402.
9. **Van der Harst P**, Volbeda M, Voors AA, Buikema H, Wassmann S, Bohm M, Nickenig G, van Gilst WH. Vascular response to angiotensin II predicts long-term prognosis in patients undergoing coronary artery bypass grafting. *Hypertension.* 2004 Dec;44(6):930-4.
10. **Van der Harst P**, van Gilst WH, Zijlstra F. Aggressive lipid-lowering therapy and regression of coronary atheroma. *JAMA.* 2004;292:39. (Letter)
11. **Van der Harst P**, Voors AA, van Veldhuisen DJ. Short-term statin therapy and cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. *Circulation.* 2004;109:e34. (Letter)
12. **Van der Harst P**, Asselbergs FW, Buikema H, Voors AA, Van Veldhuisen DJ, van Gilst WH. Effects of C-reactive protein and cholesterol on responsiveness in vitro of the internal thoracic artery to angiotensin II in patients having coronary artery bypass grafting. *Am J Cardiol.* 2006; In Press.
13. **Van der Harst P**, Voors AA, Van Gilst WH, Böhm M, Van Veldhuisen DJ. Statins in the treatment of chronic heart failure: a systematic review. *PLOS-medicine.* 2006; In press.
14. **Van der Harst P**, Voors AA, Van Gilst WH, Bohm M, Van Veldhuisen DJ. Statins in the treatment of chronic heart failure: Biological and Clinical Considerations. *Cardiovasc Res.* 2006; In press.
15. Asselbergs FW, **Van der Harst P**, van Gilst WH. Letter regarding article by Arnlov et al, "low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals". *Circulation.* 2006; In press (Letter)
16. Van der Wal RM, Gansevoort RT, **Van der Harst P**, Boomsma F, Plokker HW, van Veldhuisen DJ, De Jong PE, Van Gilst WH, Voors AA. Predictors of ACE inhibitor-induced reduction of urinary albumin excretion in non-diabetic subjects. *Hypertension.* 2006; In press.
17. Smilde TD, **Van der Harst P**, Van Veldhuisen DJ, Navis G, Voors AA, Boomsma F, Westenbrink BD, Hillege HL. Reduced Renal Perfusion in Patients with Chronic Heart Failure is the Major Determinant of Renal Dysfunction and Related to Structural Renal Damage. Submitted.
18. **Van der Harst P**, Van der Steege G, De Boer RA, Voors AA, Hall AS, Mulder MJ, Van Gilst WH, Van Veldhuisen DJ, on behalf of the MERIT-investigators. Telomere length of circulating leukocytes is decreased in patients with chronic heart failure. Submitted.
19. Van der Wal RM, **Van der Harst P**, Wagenaar LJ, Wassmann S, Morshuis WJ, Nickenig G, Buikema H, Plokker HW, Van Veldhuisen DJ, Van Gilst WH, Voors AA. Angiotensin II type 2 receptor vasoactivity in internal mammary arteries of patients with coronary artery disease. Submitted.

20. Lipsic E, Van der Meer P, **Van der Harst P**, Westenbrink BD, Koster J, Du Marchie Sarvaas GJ, Van Veldhuisen DJ, Schoemaker RG, Van Gilst WH. Low-dose erythropoietin treatment preserves cardiac function and mobilizes endothelial progenitor cells in rats with ischemic heart failure. Submitted.
21. Kuipers I, Morello F, **Van der Harst P**, Van Genne L, Van Gilst WH, Van Veldhuisen DJ, Navis G, De Boer RA. Nuclear Hormone Receptors as Regulators of the Renin-angiotensin system. Submitted.
22. **Van der Harst P**, Asselbergs FW, Hillege HL, Bakker SJL, Voors AA, Van Veldhuisen DJ, Van Gilst WH. Increase in C-reactive Protein after Withdrawal from 4 Years of Statin Therapy is Independent of Increase in LDL-cholesterol. Submitted.
23. **Van der Harst P**, Groenewegen HC, Roks AJM, Buikema H, Zijlstra F, van Gilst WH, de Smet BJGL. Rosuvastatin Attenuates Angiotensin II induced Neointimal Formation After Stent Implantation in the Rat. Submitted.
24. Groenewegen HC, **Van der Harst P**, Roks AJM, Buikema H, Zijlstra F, van Gilst WH, de Smet BJGL. Effects of Angiotensin II and Angiotensin II type 1 Receptor Blockade on Neointimal Formation after Stent Implantation. Submitted.

